A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 1

Dermatitis

Volumn 20, Issue 4, 2009, Pages 182-192

  Bremmer, Matthew ^a   Deng, April ^a   Gaspari, Anthony A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETAMETHASONE; CLOBETASOL; CORTICOSTEROID; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; ETRETIN; HYDROXYCHLOROQUINE; INFLIXIMAB; LENERCEPT; MINOXIDIL; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACNE; ALOPECIA; ALOPECIA AREATA; ANKYLOSING SPONDYLITIS; ATOPIC DERMATITIS; BACTERIAL INFECTION; BIOLOGICAL THERAPY; BULLOUS DERMATITIS; CELLULITIS; CHICKENPOX; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DERMATITIS; DERMATITIS HERPETIFORMIS; DERMATOMYOSITIS; DRESS SYNDROME; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; ECZEMA; FOLLICULITIS; GENITAL HERPES; GRANULOMA ANNULARE; GRANULOMATOSIS; HERPES SIMPLEX; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; IMPETIGO; INFECTION; LICHEN PLANUS; LICHENOID ERUPTION; LYMPHOMA; MULTIPLE MYELOMA; MYCOSIS; NEURODERMATITIS; ONYCHOMYCOSIS; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; PITYRIASIS ROSEA; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; RANDOMIZED CONTROLLED TRIAL; REBOUND; REVIEW; RHEUMATOID ARTHRITIS; SERRATIA INFECTION; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; SPONDYLOARTHROPATHY; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA; TINEA CORPORIS; TINEA VERSICOLOR; TUBERCULOSIS; TUMOR NECROSIS; ULTRAVIOLET RADIATION; VERRUCA VULGARIS; VESICULAR RASH; VIRUS INFECTION; VITILIGO;

ACNE VULGARIS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; DERMATOLOGIC AGENTS; DRUG ERUPTIONS; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LICHENOID ERUPTIONS; PRURITUS; SKIN DISEASES; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350346041     PISSN: 17103568     EISSN: None     Source Type: Journal    
DOI: 10.2310/6620.2009.09010a     Document Type: Review

References (97)

1. Saripalli YV, Gaspari A. Focus on: biologics that effect therapeutic agents in dermatology. J Drugs Derm 2005;4:233-245
2. US Food and Drug Administration: Humira (adalimumab) package insert. North Chicago, IL: Abbott Laboratories; 2002. Available at: http://www.fda.gov/ cder/foi/label/2002/adalabb123102LB.pdf (accessed October 12, 2006).
3. Lebwohl M. Psoriasis. Lancet 2003;361:1197-1204
4. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002;146:118-121 (Pubitemid 34158419)
5. US Food and Drug Administration: Enbrel (etanercept) package insert. Seattle: WA: Immunex Corp; 2004. Available at: http://www.fda.gov/cder/foi/ label/2002/etanimm091202LB.pdf (accessed October 12, 2006).
6. US Food and Drug Administration: Remicade (infliximab) package insert. Malvern, PA: Centocor Inc; 2002. Available at: http://www. fda.gov/cder/foi/ label/2002/inflcen022702LB.pdf (accessed October 12, 2006).
7. Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76.
8. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumor necrosis factor-α antagonists. Br J Dermatol 2007;156:486-491 (Pubitemid 46253946)
9. Levine T. Rituximab in the treatment of dermatomyositis: an open label pilot study. Arthritis Rheum 2005;52:601-607 (Pubitemid 40216325)
10. Connelly E, Aber C, Kleiner G, et al. Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment. Pediatr Dermatol 2007;24:172-176 (Pubitemid 46495923)
11. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002;13:1948-1950
12. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003;49(2 Suppl): s44-50.
13. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003;49(2 Suppl): S98-104.
14. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab, and adalimumab. J Dermatolog Treat 2004;15:280-294 (Pubitemid 39423287)
15. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor alpha antagonists in Sweden. Arthritis Rheum 2005;52:1986-1992 (Pubitemid 40994319)
16. Carmona JJ, Gomez-Reino V, Rodriguez-Valverde D, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-1772
17. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241-251
18. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376 (Pubitemid 44204996)
19. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population based study. Arthritis Rheum 2002;46:2287-2293
20. Van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994;53:224-228 (Pubitemid 24147188)
21. Emery P, Fleischman R, Filipowics-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400
22. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:2793-2806
23. US Food and Drug Administration: Clinical review of rituximab. San Francisco, CA: Genetech, Inc. Available at: http://www.fda.gov/cder/biologics/ review/ritugen112697-r1.pdf (accessed June 21, 2007).
24. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-1349 (Pubitemid 350060129)
25. Del Poeta G, Del Principe ML, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008;112:119-128
26. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-2164 (Pubitemid 32366969)
27. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005;23:1103-1108
28. Papp KA, Bressinck R, Fretzin S, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 2006;45:606-614
29. Dubertret L, Sterry W, Bos JD, et al. Clinical experience acquired with the efalizumab (Raptiva) (Clear) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo controlled trial. Br J Dermatol 2006;155:170-181 (Pubitemid 43876411)
30. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073-3080 (Pubitemid 37548113)
31. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-2135 (Pubitemid 41587856)
32. Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778-783
33. Lebwohl M, Blum R, Berkowitz E, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 2005;141:861-864 (Pubitemid 41058067)
34. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol 2001;45:528-536
35. Gray DT, Suman VJ, Su WP, et al. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997;133:735-740
36. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-115 (Pubitemid 350298146)
37. Tyring S, Gordon K, Poulin Y, et al. Long term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-726 (Pubitemid 46955730)
38. Esser AC, Abril A, Fayne S, Doyle JA. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 2004;50(5 Suppl):S75-7. (Pubitemid 38580526)
39. Czarnecki D. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol 2007;157:1076-1077 (Pubitemid 47583529)
40. Fryrear RS 2nd, Wiggins AK, Sanqueza O, Yosipovitch G. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol 2004;51:1026.
41. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001;45:953-956
42. Koh HK, Charif M, Weinstock MA. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:943-960
43. Adams AE, Zwicker J, Curiel C, et al. Aggressive cutaneous T-cell lymphomas after TNF-α blockade. J Am Acad Dermatol 2004;51:660-662 (Pubitemid 39278092)
44. Mahe E, Descamps V, Grossin M, et al. CD30+ T-cell lymphoma in a patient with psoriasis treated with cyclosporin and infliximab. Br J Dermatol 2003;149:170-173 (Pubitemid 36966529)
45. Woodhouse J, Maytin EV. Eruptive nevi of the palms and soles. J Am Acad Dermatol 2005;52(5 Suppl 1):S96-100.
46. Bovenschen HJ, Tjioe M, Vermaat H, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol 2006;154:880-884
47. Katsanos KH, Christodoulou DK, Zioga A, Tsianos EV. Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence? Inflamm Bowel Dis 2003;9:279.
48. Fulchiero GJ, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007;56(Suppl 5):S65-7. (Pubitemid 46552081)
49. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis. Arthritis Rheum 2007;56:3896-3908
50. Robak E, Biernat W, Krykowski E, et al. Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab. Leuk lymphoma 2005;46:909-914 (Pubitemid 40959680)
51. US Food and Drug Administration: Amevive (alefacept) package insert. Cambridge, MA: Biogen Inc; 2003. Available at: http://www.fda.gov/cder/foi/ label/2003/alefbio013003LB.htm (accessed October 14, 2006).
52. Perlmutter A, Cather J, Franks B, et al. Alefacept revisited: our 3- year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008;58:116-124 (Pubitemid 350298151)
53. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-727 (Pubitemid 36705938)
54. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-3143 (Pubitemid 30677093)
55. Voulgari PV, Markatseli TE, Exarchou SA, et al. Granuloma annulare induced by anti-tumor necrosis factor therapy. Ann Rheum Dis 2007.
56. Devos SA. Adverse skin reactions to anti-TNF-αlpha monoclonal antibody therapy. Dermatology 2003;206:388-390
57. Vergara G, Silvestre JF, Betlloch I, et al. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002;138:1258-1259 (Pubitemid 35025713)
58. Battistella M, Rivet J, Bachelez H, Liote F. Lichen planus associated with etanercept. Br J Dermatol 2008;158:188-189
59. Bovenschen JH, Kop EN, Van De Kerkhof PC, Seyger MM. Etanercept-induced lichenoid reaction pattern in psoriasis. J Dermatolog Treat 2006;17:381-383
60. De Simone C, Caldarola G, D'Agostino M, et al. Lichenoid reaction induced by adalimumab. J Eur Acad Dermatol Venereol 2008;22(5):626-627
61. US Food and Drug Administration: Raptiva (efalizumab) package insert. San Fransisco, CA: Genentech, Inc; June 2005. Available at: http://www.fda.gov/ medwatch/SAFETY/2005/Jun-PI/Raptiva-PI.pdf (accessed October 14, 2006).
62. Sladden MJ, Clarke PJ, Mitchell B. Infliximab induced acne: report of a third case. Br J Dermatol 2008;158:172. (Pubitemid 350221885)
63. Bassi E, Poli F, Charachon A, et al. Infliximab-induced acne: report of two cases. Br J Dermatol 2007;156:402-403 (Pubitemid 46095989)
64. Carson KR, Evens AM, Richey EA. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project. Blood 2009;113(20):4834-4840
65. Sobell JM, Weinberg JM. Patient fatalities potentially associated with efalizumab use. J Drugs Dermatol 2009;8:215.
66. Peck P. SDEF: Third psoriatic PML case raises more concerns about efalizumab. Medpage Today. Available at: http://www.medpagetoday.com/ meetingcoverage/SDEF/12849 (accessed April 9, 2009).
67. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
68. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35. (Pubitemid 43038667)
69. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65. (Pubitemid 46108762)
70. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-2285 (Pubitemid 43736578)
71. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-1344 (Pubitemid 47492478)
72. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-3412 (Pubitemid 41612206)
73. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (Humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-894
74. Singh SM, Rau NV, Cohen LB, Harris H. Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone. Can Med Assoc J 2004;171:1063-1064 (Pubitemid 39468715)
75. Fabre S, Gibert C, Lechiche C, et al. Primary cutaneous Nocardia otitidis-caviarum infection in a patient with rheumatoid arthritis treated with infliximab. J Rheumatol 2005;32:2432-2433 (Pubitemid 41780660)
76. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002;78:47-48 (Pubitemid 34074917)
77. Baghai M, Osmon DR, Wolk DM, et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-656 (Pubitemid 32525142)
78. Sri JC, Tsai CL, Deng A, Gaspari AA. Osteomyelitis occurring during infliximab treatment of severe psoriasis. J Drugs Dermatol 2007;6:207-210
79. Baumgart DC, Diagnass AU. Shingles following infliximab infusion. Ann Rheum Dis 2002;61:661.
80. Van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, et al. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003;29:2327-2329
81. Cursiefen C, Grunke M, Dechant C, et al. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNF-α antibody and methotrexate therapy. Am J Opthalmol 2002;134:270-271 (Pubitemid 34831835)
82. Wilson ML, Sewell LD, Mowad CM. Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab. J Drugs Dermatol 2008;7:53-54
83. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor a inhibitors. Arch Dermatol 2006;142:198-202. (Pubitemid 43276531)
84. Bremner R, Simpson E, White CR, et al. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum 2004;34:610-616 (Pubitemid 39643123)
85. Flendrie M, Creemers MC, Welsing PM, et al. Survival during treatment with tumor necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii30-3. (Pubitemid 37323597)
86. Fabre C, Dereure O. Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab. Dermatology 2008;216:185-186 (Pubitemid 351158591)
87. Tosti A, Pazzaglia M, Starace M, et al. Alopecia areata during treatment with biologic agents. Arch Dermatol 2006;142:1653-1654 (Pubitemid 44969232)
88. Garcia Bartels N, Lee HH, Worm M, et al. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol 2006;142:1654-1655 (Pubitemid 44969233)
89. Ettefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol 2004;140:1012. (Pubitemid 39062659)
90. Posten W, Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol 2005;141:759-760 (Pubitemid 41001077)
91. Dalmau J, Roé E, Corella F, et al. Acute generalized skin eruption due to adalimumab: report of two cases. J Eur Acad Dermatol Venereol 2007;21:1105-1106 (Pubitemid 47304614)
92. Smith DI, Heffernan MP. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol 2008;58(2 Suppl 1):S50-2.
93. Kent PD, Davis JM 3rd, Davis MD, Matteson FL. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum 2002;46:2257-2258
94. Bentley DD, Graves JE, Smith DI, Heffernan MP. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2006;54(5 Suppl):S242-3.
95. de Groot M, de Rie MA, Bos JD. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris. Br J Dermatol 2005;153:843-844
96. White JML, Smith CH, Robson A, et al. Dress syndrome caused by efalizumab. Clin Exp Dermatol 2007;33:50-52
97. Klein A, Szeimies RM, Landthaler M, Karrer S. Exacerbation of pityriasis rubra pilaris under efalizumab therapy. Dermatology 2007;215:72-75 (Pubitemid 46976019)